Cutaneous Leishmaniasis Market: By Drugs (Sodium Stibogluconate, Meglumine Antimoniate, Fluconazole, Ketoconazole, Miltefosine, Amphob deoxycholate / liposomal, Paromomycin, and Others), By Route of Administration (Oral, Injectable, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography

Cutaneous Leishmaniasis Market was valued at USD 51.7 million in 2023 and is projected to grow at 6.2% CAGR over the forecast years to reach USD 78.7 million by 2030. The market is driven by the increasing incidence of cutaneous leishmaniasis, rising awareness of cutaneous leishmaniasis, and the development of new treatments. Globally, an estimated 600,000 to 1 million new cases of cutaneous leishmaniasis occur annually, although only around 200,000 are reported to the World Health Organization (WHO).  About 95% of cutaneous leishmaniasis cases occur in specific regions Including parts of North America, Central America, and South America, and areas around the Mediterranean Sea, this region accounts for 80% of the cutaneous leishmaniasis cases reported worldwide, countries in the Middle East, and certain regions in Asia. Incidence of cutaneous leishmaniasis is increasing globally, driven by factors such as climate change, deforestation, and population displacement this is creating a greater demand for diagnosis and treatment products.

Additionally, there is a growing awareness of cutaneous leishmaniasis among healthcare professionals and the general public, this is leading to increased diagnosis rates and treatment uptake. Moreover, the development of new, more effective treatments for cutaneous leishmaniasis is expected to drive market growth. Despite the positive outlook, the market is hindered by constraints such as a lack of affordable diagnostics, limited treatment options, and lack of awareness. Development of new diagnostics & new treatments, and increased government funding are the cutaneous leishmaniasis market opportunities, and focus on early diagnosis, development of combination therapies, and use of new technologies are the cutaneous leishmaniasis market trends.

Cutaneous Leishmaniasis Market Key Developments:

• In July 2019, The TT4CL consortium has indeed been awarded EUR 3.75 million by Horizon 2020, the European Union’s Framework Programme for Research, and Innovation. This funding is aimed at supporting the development of an oral treatment for cutaneous leishmaniasis, which is one of the most neglected tropical diseases.
• In Oct 2018, CHEPLAPHARM has indeed acquired a product package from AmphoB deoxycholate (Fungizone®) Bristol-Myers Squibb, marking a significant expansion of its portfolio. This acquisition is part of CHEPLAPHARM’s successful expansion strategy.